|
Sections |
| Title | Starting Page | Number of Pages |
|---|
| Company Information | 1 | 1 |
| Ferring Pharmaceuticals [NonUS -- Symbol : Private] | 1 | 1 |
| Formation Date: 1950 | 1 | 1 |
| Business Summary | 1 | 1 |
| Date Category | 3 | 1 |
| Product Name Status Indication | 3 | 1 |
| Milestone | 3 | 1 |
| Product Glance | 3 | 1 |
| Trial Phase | 3 | 3 |
| Disease Hub | 3 | 2 |
| No of Products | 3 | 2 |
| Product Summary | 4 | 1 |
| Products | 4 | 2 |
| Condition Treated | 4 | 2 |
| Source Partner | 4 | 2 |
| Product Details | 5 | 1 |
| 1. Minirin Disease Hub Description | 5 | 1 |
| Therapeutic Indication Drug Class Current Trial Trial Details | 6 | 1 |
| Last Updated Partnering Details | 6 | 1 |
| 2. Pentasa Disease Hub Description | 6 | 1 |
| Last Updated 3. Pentasa Disease Hub Description | 6 | 1 |
| Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 4. Choragon Disease Hub Description | 7 | 1 |
| Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 5. Glypressin Disease Hub Description | 7 | 1 |
| Therapeutic Indication Current Trial Trial Details Last Updated 6. Lutrelef Disease Hub Description | 7 | 1 |
| Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 7. Lutrelef Disease Hub Description | 7 | 1 |
| Therapeutic | 7 | 1 |
| Indication Drug Class Current Trial Trial Details Last Updated 8. Octostim Disease Hub Description | 8 | 1 |
| Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 9. Zomacton Disease Hub Description | 8 | 1 |
| Therapeutic Indication Drug Class Current Trial Trial Details | 8 | 3 |
| Last Updated Partnering Details | 9 | 2 |
| 10. Zomacton Disease Hub Description | 9 | 1 |
| 11. Endometrin Disease Hub Description | 10 | 1 |
| Last Updated 12. Bravelle Disease Hub Description | 11 | 1 |
| Therapeutic Indication Drug Class | 11 | 1 |
| Current Trial Trial Details | 12 | 1 |
| Last Updated 13. Repronex Disease Hub Description | 12 | 1 |
| Therapeutic Indication Current Trial Trial Details Last Updated 14. Novarel Disease Hub Description | 12 | 1 |
| Therapeutic Infertility Indication Current Trial M Trial Details Presently it is available Last Updated 8/5/2008 15. | 12 | 1 |
| Description | 13 | 1 |
| Therapeutic Indication Current Trial M Trial Details Last Updated 17. Gynazole-1 Disease Hub Description | 13 | 1 |
| Therapeutic Indication Current Trial Trial Details | 13 | 2 |
| Last Updated Partnering Details | 14 | 2 |
| 18. Norprolac Disease Hub Description | 14 | 1 |
| 19. Tractocile Disease Hub Description | 14 | 1 |
| Therapeutic Indication Drug Class Current Trial Trial Details | 14 | 2 |
| Last Updated 20. Propess Disease Hub Description | 15 | 1 |
| 21. Menopur Disease Hub Description | 15 | 1 |
| Last Updated 22. Nuflexxa Disease Hub Description | 16 | 1 |
| Therapeutic Indication Current Trial | 16 | 1 |
| Trial Details | 17 | 1 |
| Last Updated Partnering Details | 18 | 1 |
| 23. Decapeptyl Depot Disease Hub Women's Description | 18 | 1 |
| Therapeutic Indication Drug Class Current Trial Trial Details Last Updated 24. Bio-Hep-B Disease Hub Description | 18 | 1 |
| Therapeutic Indication Drug Class Current Trial Trial Details | 19 | 1 |
| Last Updated 25. BioLon Disease Hub Description | 19 | 1 |
| Therapeutic Indication Current Trial Trial Details | 19 | 14 |
| Last Updated 26. BioGaia Probiotic Disease Hub Digestive Description BioGaia | 20 | 1 |
| Last Updated Partnering Details | 20 | 1 |
| 27. Prosed DS Disease Hub Description | 21 | 1 |
| Last Updated 28. Decapeptyl Disease Hub Description | 21 | 1 |
| Therapeutic Indication Current Trial Trial Details Last Updated 29. Cellegesic Disease Hub Description | 21 | 1 |
| Last Updated Partnering Details | 26 | 1 |
| 30. Fortigel Disease Hub Description | 26 | 1 |
| Last Updated Partnering Details | 28 | 3 |
| 31. Firmagon Disease Hub Description | 28 | 1 |
| 32. FE106483 Disease Hub Description | 29 | 1 |
| Last Updated 34. FE200440 Disease Hub Description | 29 | 1 |
| Therapeutic Labor Indication Current Trial II Trial Details Last Updated 35. GnRH FERRING Disease Hub Description GnRH | 30 | 1 |
| 36. FE202158 Disease Hub Description | 30 | 1 |
| Last Updated 37. FE200665 Disease Hub Description | 31 | 1 |
| Therapeutic Indication Drug Class Current Trial Trial Details | 31 | 1 |
| Last Updated 38. SciLin Disease Hub Description | 31 | 1 |
| Last Updated 8/4/2008 39. Vorozole FERRING Disease Hub Women's Description Vorozole | 31 | 1 |
| Last Updated Partnering Details | 32 | 1 |
| 40. Copper Zinc Superoxide Dismutase FERRING Disease Hub Women's Health Description Copper Zinc Superoxide Dismutase, | 32 | 1 |
| Last Updated 41. FE999011 Disease Hub Description | 32 | 1 |
| Last Updated | 32 | 1 |
| 42. BTG271 Disease Hub Description | 33 | 1 |
| Therapeutic Indication Drug Class Current Trial Trial Details | 33 | 1 |
| Last Updated 43. PABAL Disease Hub Description | 33 | 1 |
| Therapeutic Indication Current Trial Trial Details Last Updated | 33 | 1 |
| Corporate Partners | 34 | 1 |
| Jeffrey D. Hobbs -- Vice Chairman | 35 | 1 |
| Peter Wilden -- Chief Financial Officer | 35 | 1 |
| Pascal Danglas -- Executive Vice President of Clinical and Product Development | 35 | 1 |
| Lars Peter Brunse -- Executive Vice President, Technical Operations & Logistics | 35 | 1 |
| Joachim Horig -- Senior Vice President of Global Quality Assurance | 35 | 1 |
| Jonathan Grover -- Senior Vice President of Global Information Technology | 35 | 1 |
| Paul Korner -- Vice President, Medical Affairs | 35 | 1 |
| William Garbarini -- Vice President of New Orthopaedics and Urology Business Unit | 36 | 1 |
| Jean Duvall -- Secretary and Group General Counsel | 36 | 1 |
| Helene Ploix -- Director | 36 | 1 |
| Bernd Wolff -- Director | 36 | 1 |
| Alexandra -- Director | 36 | 1 |
| Helen Gallagher -- Head of Corporate Communications | 36 | 1 |
| Michael George -- Manager, Corporate Communications | 36 | 1 |
| Company Announcements | 37 | 1 |
| 9/10/2008 -- Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs | 37 | 1 |
| 7/7/2008 -- Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) 2008 Winners Announced | 37 | 1 |
| 3/20/2008 -- Ferring spins out Vantia | 37 | 1 |
| 1/30/2008 -- Launch of New, Prestigious Infertility and Gynaecology Research Grant (FRIGGA) at "Update in Infertility | 37 | 1 |
| 9/25/2007 -- Ferring Pharmaceuticals Announces Board Changes | 37 | 1 |
| 7/2/2007 -- Inequality in treatment access remains a key issue for infertile couples across Europe | 37 | 1 |
| 10/23/2006 -- Ferring Pharmaceuticals, Inc. Announces $10,000 Grand Prize Winner Of 2006 My Little Miracle Essay Contest | 38 | 1 |
| 7/6/2006 -- Ferring Pharmaceuticals Officially Opens Its Production Site and Global Administrative Headquarters | 38 | 1 |
| 2/14/2006 -- Ferring Pharmaceuticals, Inc. Announces Bruce Jenner As National Spokesperson For Euflexxa | 38 | 1 |
| 1/26/2006 -- Latest Developments in Infertility Treatment | 38 | 1 |
| 9/1/2005 -- Leading urology experts call for better recognition and treatment of nocturia | 38 | 1 |
| 4/29/2005 -- Jens Peter Norgaard Awarded Prestigious Professorship at University of Lund | 38 | 1 |
| 4/28/2005 -- Jens Peter Norgaard awarded prestigious professorship at University of Lund | 38 | 1 |
| 3/24/2005 -- Grand Opening of Ferring Pharmaceuticals (China) Co Ltd-Zhongshan Manufacturing Site | 39 | 1 |
| 12/1/2004 -- New Ferring.Com Goes Live | 39 | 1 |
| 8/1/2004 -- New Nocturia Section Launched On MINIRIN.com | 39 | 1 |
| 6/29/2004 -- Ferring Kicks Off Campaign For Newest Product NORPROLAC At The International ESHRE Conference In Ber | 39 | 1 |
| 6/29/2004 -- Experts Confirm LH Activity As An Essential Component In Infertility Treatment | 39 | 1 |
| 4/2/2004 -- Ferring Appoints President Of The Ferring Research Institute | 39 | 1 |
| 9/12/2003 -- Ferring Pharmaceuticals to Build State of the Art Production Site in Saint-Prex | 40 | 1 |
| 6/29/2003 -- The Incredible Egg | 40 | 1 |
| 6/6/2003 -- Counting the Costs of Nightly Visits to the Bathroom-Businesses lose 14 million Euros each year in reduced | 40 | 1 |
| 6/4/2003 -- Her Majesty the Queen of Sweden Addresses Salk Institute Meeting on Childhood Diseases in Stockholm | 40 | 1 |
| 4/11/2003 -- Ferring Building Receives Award | 40 | 1 |
| 3/18/2003 -- Ferring Featured In The American Medical Review Television Series | 40 | 1 |
| 3/3/2003 -- New Website About Primary Nocturnal Enuresis Opened In Scandinavia | 40 | 1 |
| 3/21/2002 -- Ferring International Center Opens for Business | 41 | 1 |
| 1/23/2002 -- Advances In Infertility | 41 | 1 |
| 1/10/2002 -- Ferring Unveils Infertility Web Site | 41 | 1 |
| 1/8/2002 -- New Ferring International Center opens for business | 41 | 1 |
| 11/28/2001 -- Professor from Canada, Winner of the Ferring Fellowship award | 41 | 1 |
| Deals & Alliances | 41 | 1 |
| 7/24/2008 -- BioGaia Completes its Latin American Market Coverage and Signs Agreement for Switzerland | 41 | 1 |
| 3/24/2008 -- Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals | 42 | 1 |
| 2/20/2008 -- BioGaia signs new agreement with Ferring Pharmaceuticals | 42 | 1 |
| 10/10/2007 -- Cosmo announces Licensing Agreement with Ferring for Budesonide MMX | 42 | 1 |
| 8/16/2007 -- deCODE biostructure Initiates New Collaboration with Ferring Research Ltd | 42 | 1 |
| 1/22/2007 -- Ferring Pharmaceuticals' Euflexxa Signs On As A Major Sponsor Of The Senior Olympics | 42 | 1 |
| 9/14/2006 -- CepTor Signs Letter of Intent with Ferring Pharmaceuticals for Superoxide Dismutase | 42 | 1 |
| 6/16/2006 -- Ferring Pharmaceuticals A/S and SciGen Limited Renegotiates Licensing Agreement for Human Insulin | 43 | 1 |
| 3/10/2006 -- BioGaia Signs Agreement with Ferring Pharmaceuticals | 43 | 1 |
| 1/31/2006 -- Ferring and Astellas enter a license agreement on Degarelix for the treatment of prostate cancer in Japan | 43 | 1 |
| 1/10/2006 -- Ranbaxy Enters Into Co-Marketing Agreement with Ferring International | 43 | 1 |
| 12/21/2005 -- Crucell and DSM Announce Second PER.C6 License Agreement with Ferring Pharmaceuticals | 43 | 1 |
| 9/29/2005 -- Holmes Herbs, Inc.: Qualia Completes Research Contract for Ferring Pharmaceuticals | 43 | 1 |
| 9/28/2005 -- PDI, Inc. selected by Ferring Pharmaceuticals to promote Euflexxa | 43 | 1 |
| 7/19/2005 -- Ferring Pharmaceuticals obtains rights to Euflexxa | 44 | 1 |
| 5/25/2005 -- Crucell N.V. and DSM Biologics announce PER.C6 license agreement with Ferring Pharmaceuticals | 44 | 1 |
| 3/23/2005 -- Savient Pharmaceuticals Enters Co-Promotion Agreement with Ferring for Nuflexxa | 44 | 1 |
| 5/18/2004 -- Protalix Biotherapeutics Announces Therapeutic Protein Development Agreement with Ferring Pharmaceuticals | 44 | 1 |
| 1/6/2004 -- Ferring Acquires NORPROLAC | 44 | 1 |
| 12/16/2003 -- Biofocus And Ferring To Collaborate On Validated Drug Target | 44 | 1 |
| 12/11/2003 -- Genaissance Pharmaceuticals and Ferring Pharmaceuticals Sign Pharmacogenomics Agreement | 44 | 1 |
| 10/31/2002 -- Ferring Pharmaceuticals and Beth Israel Deaconess Medical Center Announce Drug Discovery Collaboration | 45 | 1 |
| 9/25/2002 -- Probiodrug Grants License to Ferring and Ortho McNeil Pharmaceuticals | 45 | 1 |
| 5/28/2002 -- Arena Pharmaceuticals Announces Drug Discovery Collaboration With Ferring Pharmaceuticals | 45 | 1 |
| 9/26/2000 -- KV Signs Another Exclusive Agreement for the Marketing of Gynazole-1 | 45 | 1 |
| 6/29/2000 -- Pharmagene Attracts Four New Phase ZERO Customers and Wins New Contracts from Existing Customers | 45 | 1 |
| 1/1/1997 -- Alza licenses Testoderm CIII to Ferring Group | 45 | 1 |
| 3/1/1995 -- Ferring will Market PharmaSciences PGE2 Pessary | 45 | 1 |
| Intellectual Property | 46 | 1 |
| Mergers & Acquisitions | 46 | 1 |
| 11/17/2006 -- Dongbao To Acquire Ferring's Malmo Manufacturing Operation | 46 | 1 |
| 7/19/2005 -- Ferring acquires Savient Pharmaceuticals, Inc's global biologics manufacturing business | 46 | 1 |
| 1/12/2004 -- Ferring Acquires DUPOMAR | 46 | 1 |
| Product Update | 46 | 1 |
| 11/10/2008 -- Research Identifies Predictors for Successful IVF | 46 | 1 |
| 9/17/2008 -- Nationwide Survey Shows Infertility Patients Prefer ENDOMETRIN Compared With Other Progesterone Supplements | 47 | 1 |
| 5/9/2008 -- ProStrakan announces positive results from pivotal US "Fortify" study on Fortigel (testosterone 2% gel) | 47 | 1 |
| 4/18/2008 -- Ferring Pharmaceuticals' Euflexxa to Serve as Sponsor for Sprint Force America Masters Track Club | 47 | 1 |
| 3/27/2008 -- Positive Phase III Data Unveiled for New GnRH Blocker Degarelix | 47 | 1 |
| 2/28/2008 -- Ferring Pharmaceuticals Submits New Drug Application For Degarelix | 48 | 1 |
| 1/22/2008 -- Vyteris Announces First Successful Non-Invasive Delivery of Peptide Using Smart Patch Technology | 48 | 1 |
| 12/3/2007 -- Ferring Pharmaceuticals Completes Phase III Study of Degarelix in Prostate Cancer Patients | 48 | 1 |
| 10/30/2007 -- Superior remission rates for once daily use of Pentasa (mesalazine) in ulcerative colitis | 48 | 1 |
| 8/20/2007 -- ProStrakan announces commencement of recruitment in pivotal US Trials for Cellegesic (nitroglycerin) | 49 | 1 |
| 8/20/2007 -- ProStrakan announces commencement of recruitment in pivotal US Trials for Fortigel (Tostran) | 49 | 1 |
| 7/2/2007 -- New Data Demonstrates Both Cost And Efficacy Benefit Of Menopur Compared To Recombinant FSH Treatment | 49 | 1 |
| 6/11/2007 -- UK Launch of ProStrakan's Latest Pan EU Product Tostran (2% testosterone gel) | 49 | 1 |
| 4/18/2007 -- Ferring Reports on Endometrin Presentations at Pacific Coast Reproductive Society Annual Meeting | 49 | 1 |
| 6/19/2006 -- IVF Treatment with Menopur Results in Significantly Higher Rate of Live Births Compared to Recombinant | 49 | 1 |
| 4/7/2006 -- Degarelix, a novel GnRH blocker from Ferring, moves into phase III | 50 | 1 |
| 11/14/2005 -- Ferring Pharmaceuticals A/S Announces Launch of Euflexxa for Osteoarthritis Knee Pain | 50 | 1 |
| 6/20/2005 -- New study adds weight to clinical MERiT of Menopur in IVF | 50 | 1 |
| 4/11/2005 -- Ferring Pharmaceuticals Announces Launch Of New Treatment For Infertility | 50 | 1 |
| 10/18/2004 -- Ferring Pharmaceuticals, Inc. Introduces Bravelle With First Needle-Free Reconstitution Device | 50 | 1 |
| 10/15/2003 -- New infertility study-Significant difference between treatments | 51 | 1 |
| 11/8/2002 -- 5-ASAs/mesalazine May Lower Colorectal Cancer Risk in Inflammatory Bowel Disease | 51 | 1 |
| 5/16/2002 -- Ferring Launches a New No Needle Device at 2nd Ferring International Paediatric Endocrinology Symposium | 51 | 1 |
| 7/1/2001 -- TREASURE Trial in Europe | 51 | 1 |
| 6/18/2001 -- New Data Revealed on HP-FSH Product | 51 | 1 |
| Regulatory | 51 | 1 |
| 11/5/2008 -- Antares Announces Additional Regulatory Approvals in Europe and Australia for Its Needle-Free Injection | 51 | 1 |
| 9/9/2004 -- KV Pharmaceutical Company Licensing Partner Ferring, Inc. Receives Approval To Market Gynazole-1 In Canada | 52 | 1 |
| 5/6/2002 -- FDA Approves Bravelle (urofollitropin for injection, purified) | 52 | 1 |
